Ventricular septal defects
- Overview
- Theory
- Diagnosis
- Management
- Follow up
- Resources
Treatment algorithm
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer
congenital: small
observation
In cases of small restrictive ventricular septal defects with a pulmonary-systemic blood flow ratio (Qp:Qs) <1.5:1, observation and follow-up is all that is generally indicated.[2]Stout KS, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Apr 2;139(14):e698-800. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000603 http://www.ncbi.nlm.nih.gov/pubmed/30586767?tool=bestpractice.com
Small restrictive defects detected at birth without symptoms close spontaneously in most cases, and the prognosis of those that fail to close is excellent.[2]Stout KS, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Apr 2;139(14):e698-800. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000603 http://www.ncbi.nlm.nih.gov/pubmed/30586767?tool=bestpractice.com
prophylactic antibiotics
Treatment recommended for SOME patients in selected patient group
Endocarditis is a complication of ventricular septal defects (VSDs), and a high index of suspicion must be maintained.
Infective endocarditis often presents nonspecifically, and most commonly involves fever with possible physical signs of peripheral emboli (Osler nodes, Roth spots, or Janeway lesions).
Prophylactic antibiotics are now only indicated in patients at particularly high risk of developing endocarditis.[2]Stout KS, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Apr 2;139(14):e698-800. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000603 http://www.ncbi.nlm.nih.gov/pubmed/30586767?tool=bestpractice.com In patients with a small VSD, this includes those with a previous history of infective endocarditis. Prophylaxis is no longer recommended for routine gastrointestinal procedures.
Primary options
amoxicillin: children: 50 mg/kg orally one hour before procedure; adults: 2 g orally one hour before procedure
OR
clindamycin: children: 20 mg/ kg orally one hour before procedure; adults: 600 mg orally one hour before procedure
More clindamycinClindamycin is an alternative to penicillin in patients with penicillin allergy
congenital: medium or large
corrective closure
Medium or large ventricular septal defects (VSDs) should be closed to prevent progression to severe pulmonary hypertension, heart failure, and Eisenmenger syndrome.[2]Stout KS, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Apr 2;139(14):e698-800. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000603 http://www.ncbi.nlm.nih.gov/pubmed/30586767?tool=bestpractice.com
Surgical closure is recommended in adults with evidence of left ventricular volume overload and hemodynamically significant shunts (a pulmonary-systemic blood flow ratio [Qp:Qs] ≥1.5:1) if: pulmonary artery (PA) systolic pressure is <50% systemic and pulmonary vascular resistance is less than one third systemic. Surgical closure may be considered: when a perimembranous or supracristal VSD causes worsening aortic regurgitation; with a history of infective endocarditis; or when PA systolic pressure is ≥50% systemic and/or pulmonary vascular resistance is greater than one third systemic with a left-to-right shunt (Qp:Qs ≥1.5:1).[2]Stout KS, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Apr 2;139(14):e698-800. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000603 http://www.ncbi.nlm.nih.gov/pubmed/30586767?tool=bestpractice.com
The usual procedure is open surgery in which a patch (bovine pericardium or synthetic material) is used to close the VSD.[2]Stout KS, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Apr 2;139(14):e698-800. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000603 http://www.ncbi.nlm.nih.gov/pubmed/30586767?tool=bestpractice.com One study found that surgical repair and transcatheter device closure of perimembranous VSDs in children were equally effective, with transcatheter closure being associated with shorter hospital stay, less blood transfused, and lower cost.[28]Yang J, Yang L, Yu S, et al. Transcatheter versus surgical closure of perimembranous ventricular septal defects in children: a randomized controlled trial. J Am Coll Cardiol. 2014 Apr 1;63(12):1159-68. https://www.sciencedirect.com/science/article/pii/S0735109714002927?via%3Dihub http://www.ncbi.nlm.nih.gov/pubmed/24509270?tool=bestpractice.com
Percutaneous device closure is an option for type 4 (muscular) and some forms of type 2 (perimembranous) defects, especially if the defect is away from the tricuspid valve and the aorta.[29]Szkutnik M, Qureshi SA, Kusa J, et al. Use of the Amplatzer muscular ventricular septal defect occluder for closure of perimembranous ventricular septal defects. Heart. 2007 Mar;93(3):355-8. http://www.ncbi.nlm.nih.gov/pubmed/16980519?tool=bestpractice.com [30]Masura J, Gao W, Gavora P, et al. Percutaneous closure of perimembranous ventricular septal defects with the eccentric Amplatzer device: multicenter follow-up study. Pediatr Cardiol. 2005 May-Jun;26(3):216-9. http://www.ncbi.nlm.nih.gov/pubmed/16082578?tool=bestpractice.com [31]Fu YC, Bass J, Amin Z, et al. Transcatheter closure of perimembranous ventricular septal defects using the new Amplatzer membranous VSD occluder: results of the U.S. phase I trial. J Am Coll Cardiol. 2006 Jan 17;47(2):319-25. http://www.ncbi.nlm.nih.gov/pubmed/16412854?tool=bestpractice.com [32]Butera G, Carminati M, Chessa M, et al. Transcatheter closure of perimembranous ventricular septal defects: early and long-term results. J Am Coll Cardiol. 2007 Sep 18;50(12):1189-95. http://www.ncbi.nlm.nih.gov/pubmed/17868812?tool=bestpractice.com
prophylactic antibiotics
Treatment recommended for SOME patients in selected patient group
Endocarditis is a complication of ventricular septal defects, and a high index of suspicion must be maintained.
Infective endocarditis often presents nonspecifically, and most commonly involves fever with possible physical signs of peripheral emboli (Osler nodes, Roth spots, or Janeway lesions).
Prophylactic antibiotics are now only indicated in patients at particularly high risk of developing endocarditis.[2]Stout KS, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Apr 2;139(14):e698-800. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000603 http://www.ncbi.nlm.nih.gov/pubmed/30586767?tool=bestpractice.com This includes patients with a previous history of infective endocarditis, patients within 6 months following patch repair or percutaneous device closure, or patients with a residual defect following closure. Prophylaxis is no longer recommended for routine gastrointestinal procedures.
Primary options
amoxicillin: children: 50 mg/kg orally one hour before procedure; adults: 2 g orally one hour before procedure
OR
clindamycin: children: 20 mg/ kg orally one hour before procedure; adults: 600 mg orally one hour before procedure
More clindamycinClindamycin is an alternative to penicillin in patients with penicillin allergy
preoperative medical therapy
Medical therapy is not curative and is used to control heart failure symptoms prior to surgery. This is mainly required in infants to delay closure until the infant has grown enough and surgery can be performed; these therapies are almost never required in adults.
Medications include diuretics, and in some cases ACE inhibitors and digoxin.[2]Stout KS, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Apr 2;139(14):e698-800. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000603 http://www.ncbi.nlm.nih.gov/pubmed/30586767?tool=bestpractice.com [33]Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3;145(18):e895-e1032. https://www.doi.org/10.1161/CIR.0000000000001063 http://www.ncbi.nlm.nih.gov/pubmed/35363499?tool=bestpractice.com
Anemia, if present, should be corrected by red blood cell transfusion, or by iron therapy in case of iron-deficiency anemia.
Primary options
furosemide: children: consult specialist for guidance on dose
Secondary options
furosemide: children: consult specialist for guidance on dose
-- AND --
captopril: children: consult specialist for guidance on dose
or
enalapril: children: consult specialist for guidance on dose
-- AND --
digoxin: children: consult specialist for guidance on dose
corrective closure
Treatment recommended for ALL patients in selected patient group
The development of heart failure symptoms is an indication for surgery. Surgical closure should be considered with: a pulmonary-systemic blood flow ratio (Qp:Qs) ≥1.5:1; a perimembranous or supracristal ventricular septal defect (VSD) causing worsening aortic regurgitation; or a history of endocarditis.[2]Stout KS, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Apr 2;139(14):e698-800. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000603 http://www.ncbi.nlm.nih.gov/pubmed/30586767?tool=bestpractice.com Surgery can be performed once heart failure symptoms have been controlled with therapy.
The usual procedure is open surgery in which a patch (bovine pericardium or synthetic material) is used to close the VSD.[2]Stout KS, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Apr 2;139(14):e698-800. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000603 http://www.ncbi.nlm.nih.gov/pubmed/30586767?tool=bestpractice.com One study found that surgical repair and transcatheter device closure of perimembranous VSDs in children were equally effective, with transcatheter closure being associated with shorter hospital stay, less blood transfused, and lower cost.[28]Yang J, Yang L, Yu S, et al. Transcatheter versus surgical closure of perimembranous ventricular septal defects in children: a randomized controlled trial. J Am Coll Cardiol. 2014 Apr 1;63(12):1159-68. https://www.sciencedirect.com/science/article/pii/S0735109714002927?via%3Dihub http://www.ncbi.nlm.nih.gov/pubmed/24509270?tool=bestpractice.com
Percutaneous device closure is an option for type 4 (muscular) and some forms of type 2 (perimembranous) defects, especially if they are away from the tricuspid valve or the aorta.[29]Szkutnik M, Qureshi SA, Kusa J, et al. Use of the Amplatzer muscular ventricular septal defect occluder for closure of perimembranous ventricular septal defects. Heart. 2007 Mar;93(3):355-8. http://www.ncbi.nlm.nih.gov/pubmed/16980519?tool=bestpractice.com [30]Masura J, Gao W, Gavora P, et al. Percutaneous closure of perimembranous ventricular septal defects with the eccentric Amplatzer device: multicenter follow-up study. Pediatr Cardiol. 2005 May-Jun;26(3):216-9. http://www.ncbi.nlm.nih.gov/pubmed/16082578?tool=bestpractice.com [31]Fu YC, Bass J, Amin Z, et al. Transcatheter closure of perimembranous ventricular septal defects using the new Amplatzer membranous VSD occluder: results of the U.S. phase I trial. J Am Coll Cardiol. 2006 Jan 17;47(2):319-25. http://www.ncbi.nlm.nih.gov/pubmed/16412854?tool=bestpractice.com [32]Butera G, Carminati M, Chessa M, et al. Transcatheter closure of perimembranous ventricular septal defects: early and long-term results. J Am Coll Cardiol. 2007 Sep 18;50(12):1189-95. http://www.ncbi.nlm.nih.gov/pubmed/17868812?tool=bestpractice.com
prophylactic antibiotics
Treatment recommended for SOME patients in selected patient group
Endocarditis is a complication of ventricular septal defects, and a high index of suspicion must be maintained.
Infective endocarditis often presents nonspecifically, and most commonly involves fever with possible physical signs of peripheral emboli (Osler nodes, Roth spots, or Janeway lesions).
Prophylactic antibiotics are now only indicated in patients at particularly high risk of developing endocarditis.[2]Stout KS, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Apr 2;139(14):e698-800. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000603 http://www.ncbi.nlm.nih.gov/pubmed/30586767?tool=bestpractice.com This includes patients with a previous history of infective endocarditis, patients within 6 months following patch repair or percutaneous device closure, or patients with a residual defect following closure. Prophylaxis is no longer recommended for routine gastrointestinal procedures.
Primary options
amoxicillin: children: 50 mg/kg orally one hour before procedure; adults: 2 g orally one hour before procedure
OR
clindamycin: children: 20 mg/ kg orally one hour before procedure; adults: 600 mg orally one hour before procedure
More clindamycinClindamycin is an alternative to penicillin in patients with penicillin allergy
supportive medical therapy with pulmonary vasodilators
If patients progress to shunt reversal with Eisenmenger syndrome, the ventricular septal defect is inoperable and treatment is supportive with pharmacotherapy.[5]Arvanitaki A, Giannakoulas G, Baumgartner H, et al. Eisenmenger syndrome: diagnosis, prognosis and clinical management. Heart. 2020 Nov;106(21):1638-45. http://www.ncbi.nlm.nih.gov/pubmed/32690623?tool=bestpractice.com
Drugs used to treat pulmonary hypertension include phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil), endothelin receptor antagonists (e.g., bosentan, ambrisentan), and prostacyclins (e.g., epoprostenol).[24]Jone PN, Ivy DD, Hauck A, et al. Pulmonary hypertension in congenital heart disease: a scientific statement from the American Heart Association. Circ Heart Fail. 2023 Jul;16(7):e00080. https://www.ahajournals.org/doi/full/10.1161/HHF.0000000000000080 http://www.ncbi.nlm.nih.gov/pubmed/37357777?tool=bestpractice.com
Sildenafil and tadalafil have been shown to improve exercise capacity and hemodynamics in patients with Eisenmenger syndrome.[24]Jone PN, Ivy DD, Hauck A, et al. Pulmonary hypertension in congenital heart disease: a scientific statement from the American Heart Association. Circ Heart Fail. 2023 Jul;16(7):e00080. https://www.ahajournals.org/doi/full/10.1161/HHF.0000000000000080 http://www.ncbi.nlm.nih.gov/pubmed/37357777?tool=bestpractice.com [34]Chau EM, Fan KY, Chow WH. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol. 2007 Sep 3;120(3):301-5. http://www.ncbi.nlm.nih.gov/pubmed/17174418?tool=bestpractice.com However, the US Food and Drug Administration (FDA) does not recommend the use of these agents for this indication in pediatric patients due to an increased risk of mortality with higher doses in one trial, unless the medical team consider that the benefits of treatment with the drug are likely to outweigh its potential risks.[35]Barst RJ, Ivy DD, Gaitan G, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation. 2012 Jan 17;125(2):324-34. http://www.ncbi.nlm.nih.gov/pubmed/22128226?tool=bestpractice.com Revatio (sildenafil): drug safety communication - FDA clarifies warning about pediatric use for pulmonary arterial hypertension Opens in new window
Bosentan and ambrisentan have also been shown to improve hemodynamics in Eisenmenger syndrome, but larger studies are needed.[24]Jone PN, Ivy DD, Hauck A, et al. Pulmonary hypertension in congenital heart disease: a scientific statement from the American Heart Association. Circ Heart Fail. 2023 Jul;16(7):e00080. https://www.ahajournals.org/doi/full/10.1161/HHF.0000000000000080 http://www.ncbi.nlm.nih.gov/pubmed/37357777?tool=bestpractice.com [36]Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006 Jul 4;114(1):48-54. http://www.ncbi.nlm.nih.gov/pubmed/16801459?tool=bestpractice.com
Epoprostenol may be an alternative option to these agents.[37]Fernandes SM, Newburger JW, Lang P, et al. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology. Am J Cardiol. 2003 Mar 1;91(5):632-5. http://www.ncbi.nlm.nih.gov/pubmed/12615282?tool=bestpractice.com [38]Luna-Lopez R, Segura de la Cal T, Sarnago Cebada F, et al. Triple vasodilator therapy in pulmonary arterial hypertension associated with congenital heart disease. Heart. 2024 Feb 12;110(5):346-52. http://www.ncbi.nlm.nih.gov/pubmed/37903556?tool=bestpractice.com [39]Ferrero P, Krishnathasan K, Constantine A, et al. Pulmonary arterial hypertension in congenital heart disease. Heart. 2023 Nov 14:heartjnl-2023-322890.
Monotherapy or combination therapy with these agents may be recommended, and the choice of regimen should be decided in consult with a specialist.
prophylactic antibiotics
Treatment recommended for ALL patients in selected patient group
Endocarditis is a complication of ventricular septal defects, and a high index of suspicion must be maintained.
Infective endocarditis often presents nonspecifically, and most commonly involves fever with possible physical signs of peripheral emboli (Osler nodes, Roth spots, or Janeway lesions).
Antibiotic prophylaxis is indicated in all patients with Eisenmenger syndrome.[2]Stout KS, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Apr 2;139(14):e698-800. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000603 http://www.ncbi.nlm.nih.gov/pubmed/30586767?tool=bestpractice.com
Primary options
amoxicillin: children: 50 mg/kg orally one hour before procedure; adults: 2 g orally one hour before procedure
OR
clindamycin: children: 20 mg/ kg orally one hour before procedure; adults: 600 mg orally one hour before procedure
More clindamycinClindamycin is an alternative to penicillin in patients with penicillin allergy
monitoring and treatment of hyperviscosity
Treatment recommended for SOME patients in selected patient group
Patients with Eisenmenger syndrome frequently develop erythrocytosis to compensate for the hypoxemia, and some of them develop hyperviscosity.[5]Arvanitaki A, Giannakoulas G, Baumgartner H, et al. Eisenmenger syndrome: diagnosis, prognosis and clinical management. Heart. 2020 Nov;106(21):1638-45. http://www.ncbi.nlm.nih.gov/pubmed/32690623?tool=bestpractice.com Hyperviscosity manifests with headache, fatigue, dyspnea, and dizziness. Phlebotomy and intravenous infusion of saline may be performed in select patients if symptoms of hyperviscosity are severe.[5]Arvanitaki A, Giannakoulas G, Baumgartner H, et al. Eisenmenger syndrome: diagnosis, prognosis and clinical management. Heart. 2020 Nov;106(21):1638-45. http://www.ncbi.nlm.nih.gov/pubmed/32690623?tool=bestpractice.com Routine phlebotomy for asymptomatic erythrocytosis is not indicated. Anemia and volume depletion can cause similar symptoms and should be excluded before starting this type of therapy.[5]Arvanitaki A, Giannakoulas G, Baumgartner H, et al. Eisenmenger syndrome: diagnosis, prognosis and clinical management. Heart. 2020 Nov;106(21):1638-45. http://www.ncbi.nlm.nih.gov/pubmed/32690623?tool=bestpractice.com
heart-lung transplantation
In some patients who are severely symptomatic, heart-lung transplant may be considered and, when feasible, surgical correction of the ventricular septal defect together with lung transplant may be considered.[5]Arvanitaki A, Giannakoulas G, Baumgartner H, et al. Eisenmenger syndrome: diagnosis, prognosis and clinical management. Heart. 2020 Nov;106(21):1638-45. http://www.ncbi.nlm.nih.gov/pubmed/32690623?tool=bestpractice.com [24]Jone PN, Ivy DD, Hauck A, et al. Pulmonary hypertension in congenital heart disease: a scientific statement from the American Heart Association. Circ Heart Fail. 2023 Jul;16(7):e00080. https://www.ahajournals.org/doi/full/10.1161/HHF.0000000000000080 http://www.ncbi.nlm.nih.gov/pubmed/37357777?tool=bestpractice.com The survival of patients with Eisenmenger syndrome who receive a heart-lung transplant is similar to that of other heart-lung transplant recipients, or better, despite a more difficult operative course.[24]Jone PN, Ivy DD, Hauck A, et al. Pulmonary hypertension in congenital heart disease: a scientific statement from the American Heart Association. Circ Heart Fail. 2023 Jul;16(7):e00080. https://www.ahajournals.org/doi/full/10.1161/HHF.0000000000000080 http://www.ncbi.nlm.nih.gov/pubmed/37357777?tool=bestpractice.com [44]Christie JD, Edwards LB, Kucheryavaya AY, et al. The registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant. 2012 Oct;31(10):1073-86. https://www.jhltonline.org/article/S1053-2498(12)01212-0/fulltext
acquired
corrective closure following intra-aortic balloon pump insertion ± coronary artery bypass graft
Patients generally present with acute left-heart failure, and mortality without surgery is extremely high.[6]Birnbaum Y, Fishbein MC, Blanche C, et al. Ventricular septal defect after acute myocardial infarction. New Engl J Med. 2002 Oct 31;347(18):1426-32. http://www.ncbi.nlm.nih.gov/pubmed/12409546?tool=bestpractice.com Mortality is much lower with urgent surgery.
Generally, patients undergo coronary angiography and intra-aortic balloon pump insertion prior to surgery in order to define coronary anatomy for possible coronary artery bypass graft (CABG) and to stabilize the patient with the intra-aortic balloon pump. CABG is carried out at the same time as the corrective closure.[6]Birnbaum Y, Fishbein MC, Blanche C, et al. Ventricular septal defect after acute myocardial infarction. New Engl J Med. 2002 Oct 31;347(18):1426-32.
http://www.ncbi.nlm.nih.gov/pubmed/12409546?tool=bestpractice.com
[ ]
What effect does using a preoperative intra-aortic balloon pump (IABP) have on mortality and morbidity in people undergoing coronary artery bypass grafting (CABG)?/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.343/fullShow me the answer Concomitant coronary revascularization appears to improve outcomes.[40]Perrotta S, Lentini S. In patients undergoing surgical repair of post-infarction ventricular septal defect, does concomitant revascularization improve prognosis? Interact Cardiovasc Thorac Surg. 2009 Nov;9(5):879-87.
http://icvts.oxfordjournals.org/content/9/5/879.full
http://www.ncbi.nlm.nih.gov/pubmed/19692439?tool=bestpractice.com
Percutaneous device closure is an option if the risks of open surgical closure are too high.[41]Landzberg MJ, Lock JE. Transcatheter management of ventricular septal rupture after myocardial infarction. Semin Thorac Cardiovasc Surg. 1998 Apr;10(2):128-32. http://www.ncbi.nlm.nih.gov/pubmed/9620460?tool=bestpractice.com [42]Pesonen E, Thilen U, Sandstrom S, et al. Transcatheter closure of post-infarction ventricular septal defect with the Amplatzer Septal Occluder device. Scand Cardiovasc J. 2000 Aug;34(4):446-8. http://www.ncbi.nlm.nih.gov/pubmed/10983682?tool=bestpractice.com [45]Pienvichit P, Piemonte TC. Percutaneous closure of postmyocardial infarction ventricular septal defect with the CardioSEAL septal occluder implant. Catheter Cardiovasc Interv. 2001 Dec;54(4):490-4. http://www.ncbi.nlm.nih.gov/pubmed/11747187?tool=bestpractice.com These patients still receive an angiogram and intra-aortic balloon insertion.
prophylactic antibiotics
Treatment recommended for SOME patients in selected patient group
Endocarditis is a complication of ventricular septal defects (VSDs), and a high index of suspicion must be maintained.
Infective endocarditis often presents nonspecifically, and most commonly involves fever with possible physical signs of peripheral emboli (Osler nodes, Roth spots, or Janeway lesions).
Prophylactic antibiotics are now only indicated in patients at particularly high risk of developing endocarditis: patients with Eisenmenger syndrome; patients with a previous history of infective endocarditis; patients within 6 months following patch repair or percutaneous device closure of VSD; or patients with a residual defect following closure. Prophylaxis is no longer recommended for routine gastrointestinal procedures.[2]Stout KS, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Apr 2;139(14):e698-800. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000603 http://www.ncbi.nlm.nih.gov/pubmed/30586767?tool=bestpractice.com
Primary options
amoxicillin: children: 50 mg/kg orally one hour before procedure; adults: 2 g orally one hour before procedure
OR
clindamycin: children: 20 mg/ kg orally one hour before procedure; adults: 600 mg orally one hour before procedure
More clindamycinClindamycin is an alternative to penicillin in patients with penicillin allergy
corrective closure
A traumatic ventricular septal defect is generally treated with surgical repair of the defect in patients with significant-sized defects. Small defects with insignificant shunts may be managed conservatively.
prophylactic antibiotics
Treatment recommended for SOME patients in selected patient group
Endocarditis is a complication of ventricular septal defects (VSDs), and a high index of suspicion must be maintained.
Infective endocarditis often presents nonspecifically, and most commonly involves fever with possible physical signs of peripheral emboli (Osler nodes, Roth spots, or Janeway lesions).
Prophylactic antibiotics are now only indicated in patients at particularly high risk of developing endocarditis: patients with Eisenmenger syndrome; patients with a previous history of infective endocarditis; patients within 6 months following patch repair or percutaneous device closure of VSD; or patients with a residual defect following closure. Prophylaxis is no longer recommended for routine gastrointestinal procedures.[2]Stout KS, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Apr 2;139(14):e698-800. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000603 http://www.ncbi.nlm.nih.gov/pubmed/30586767?tool=bestpractice.com
Primary options
amoxicillin: children: 50 mg/kg orally one hour before procedure; adults: 2 g orally one hour before procedure
OR
clindamycin: children: 20 mg/ kg orally one hour before procedure; adults: 600 mg orally one hour before procedure
More clindamycinClindamycin is an alternative to penicillin in patients with penicillin allergy
Choose a patient group to see our recommendations
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups. See disclaimer
Use of this content is subject to our disclaimer